Drugs / Enapotamab vedotin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02988817 | Nov 2016 → Nov 2021 | cervical cancer, endometrial cancer, melanoma, non-small cell lung carcinoma +3 | Genmab | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enapotamab vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02988817 ↗ |
| Known as | Axl-107-mmae | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297987 ↗ |
| Known as | Enapotamab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297987 ↗ |
| Known as | Enapotamab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297987 ↗ |
| Known as | HuMax-AXL-ADC | “Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.” NCT02988817 ↗ |
| Route | Intravenous | “Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.” NCT02988817 ↗ |
| Target | AXL | “Axl-specific Antibody-drug Conjugate” NCT02988817 ↗ |